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Signaling Antagonists and Agonists
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ABSTRACT
Although adipose-derived stem cells (ASCs) are an attractive cell source for bone tissue engineering,
direct useofASCs alonehashad limited success in the treatment of large bonedefects. Althoughbone
morphogenetic proteins (BMPs) arebelieved tobe themostpotentosteoinductive factors topromote
osteogenic differentiation of ASCs, their clinical applications require supraphysiological dosage, lead-
ing to high medical burden and adverse side effects. In the present study, we demonstrated an alter-
native approach that can effectively complement the BMP activity to maximize the osteogenesis of
ASCs without exogenous application of BMPs by regulating levels of antagonists and agonists to
BMP signaling. Treatment of ASCs with the amiloride derivative phenamil, a positive regulator of BMP
signaling, combined with gene manipulation to suppress the BMP antagonist noggin, significantly
enhanced osteogenic differentiation of ASCs through increased BMP–Smad signaling in vitro.
Furthermore, the combination approach of noggin suppression and phenamil stimulation enhanced
the BMP signaling and bone repair in a mouse calvarial defect model by adding noggin knockdown
ASCs to apatite-coated poly(lactic-coglycolic acid) scaffolds loaded with phenamil. These results sug-
gestnovel complementaryosteoinductive strategies that couldmaximizeactivityof theBMPpathway
inASCbone repairwhile reducingpotential adverseeffectsof currentBMP-based therapeutics. STEM
CELLS TRANSLATIONALMEDICINE 2016;5:539–551
SIGNIFICANCE
Although stem cell-based tissue engineering strategy offers a promising alternative to repair dam-
aged bone, direct use of stem cells alone is not adequate for challenging healing environments such
as in large bone defects. This study demonstrates a novel strategy tomaximize bone formation path-
ways in osteogenic differentiation ofmesenchymal stemcells and functional bone formation by com-
bining genemanipulation with a small molecule activator toward osteogenesis. The findings indicate
promising stem cell-based therapy for treating bone defects that can effectively complement or re-
place current osteoinductive therapeutics.
INTRODUCTION
Bone defects caused by traumatic injury, tumor
extirpation, and degenerative diseases are chal-
lenging health problems [1]. A cell-based tissue-
engineering strategy offers a promising alternative
to repair or regenerate the damaged bone [2]. Al-
though mesenchymal stem cells (MSCs) derived
from adipose tissues are a readily available cell
source for bone tissue engineering, direct use of
adipose-derived stem cells (ASCs) alone has had
limited success in the repair of large bone defects
[3, 4]. Thus, there is an increasing interest in
employing the use of osteoinductive factors to en-
hance osteogenesis of ASCs [5, 6]. Although bone
morphogenetic proteins (BMPs) are considered
themost potent osteoinductive factors, supraphy-
siological dosage of BMPs is required for clinical
bone treatment,whichwould increase themedical
cost and could cause undesired adverse effects
such as life-threatening tissue swelling, ectopic
bone, and cancer [7–12]. To provide a safe and
cost-efficient treatment, it is necessary toestablish
an alternative osteoinductive strategy that can ef-
fectively complement the activity of BMP in osteo-
genesis of ASCs.
One potential approach is to deliver no ex-
ogenous BMPs, while enhancing endogenous
BMP activities in ASC osteogenesis by inhibit-
ing negative regulators of BMP signaling. BMP
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signaling is negatively regulated by various extramembranous
and intracellular antagonists such as noggin, chordin, gremlin,
and ubiquitin ligase Smad ubiquitination regulatory factor
(Smurf1) [13, 14]. Noggin is a BMP antagonist by interfering
with BMP binding to its cell receptors [15–17]. In response to
BMPs, osteoblastic cells were revealed to upregulate the ex-
pression of noggin as part of a negative feedback loop to regu-
late increased levels of BMP signaling [18]. Several studies
previously reported that the application of exogenous noggin
impaired both in vitro osteogenesis and in vivo bone formation,
whereas use of noggin-neutralizing antibodies improved bone
repair [19–21]. We recently reported that noggin knockdown
enhanced BMP-induced osteogenesis of ASCs in vitro and bone
formation in vivo [22, 23].
The potency of endogenous BMP signaling can be further
enhanced by delivering small molecule compounds that can in-
duce osteogenic differentiation through BMP–Smad signaling,
such as phenamil. In comparison with growth factor proteins,
small osteoinductive molecules present several advantages
such as relatively low cost (easy synthesis), high stability, and
low immunogenicity [24]. The smallmolecule phenamil, a deriv-
ative of the U.S. Food and Drug Administration-approved
diuretic amiloride, is currently attracting attention in bone
regeneration due to its osteogenic efficacy through the BMP–
Smad signaling pathways [25]. Phenamil induces osteogenic dif-
ferentiation in mouse bone marrow stromal or preosteoblastic
cells and human dental pulp cells [26, 27]. We recently reported
the osteogenic activity of phenamil in vitro and bone formation
in vivo in a calvarial defect model, both alone and in combina-
tion with BMP-2 utilizing a reduced BMP-2 dose [28]. The oste-
ogenic activity of phenamil has been reported to be mediated
by downregulating BMP antagonist Smurf1 and stabilizing Smads
through induction of tribbles homolog 3 (Trb3), thereby stimulat-
ing BMP signaling [25, 28, 29].
Here, we seek to enhance BMP–Smad signaling by inhibiting
expression of a BMP antagonist (noggin) and delivering a small
molecule activator of BMP signaling (phenamil) for maximal
ASC osteogenesis without exogenous application of BMPs. We
downregulated noggin in ASCs using an RNA interference strat-
egy, and their osteogenic differentiation through BMP–Smad sig-
naling was evaluated with phenamil treatment in vitro. We
further investigated the complementary approach of noggin sup-
pression and phenamil stimulation to enhance the BMP–Smad
signaling and bone repair in a calvarial defect model using
apatite-coated poly(lactic-coglycolic acid) (Ap-PLGA) scaffold
loaded with noggin knockout ASCs and phenamil. Our study
demonstrated that the combination of noggin suppression and
phenamil treatment is an effective strategy to enhance osteogen-
esis of ASCs; such a strategy couldmaximize activity of BMP–Smad
pathway in bone regeneration while minimizing BMP-mediated
adverse effects.
MATERIALS AND METHODS
Animals
All animal studies were performed by using protocols approved
by the University of California, Los Angeles (UCLA) Animal Re-
search Committee and were in compliance with Guidelines for
the Care and Use of Laboratory Animals of the National Institutes
of Health.
Isolation and Culture of ASCs
Cells were harvested from inguinal fat pads of male C57BL/6
mice (Charles River Laboratories, Wilmington, MA, http://
www.criver.com) at the age of 4–8 weeks, according to previ-
ous protocols established, because these cells were shown to
differentiate into osteogenic lineage in our previous studies
[22, 23]. The collected adipose tissues were rinsed in sterile
phosphate-buffered saline (PBS), cut into small pieces, and
then digested with 0.1% collagenase type I (Sigma-Aldrich, St.
Louis, MO, http://www.sigmaaldrich.com). After 2 hours of
digestion, cells were released from adipose tissues and were
subjected to centrifugation at 1,200 rpm for 5 minutes. Finally,
the cells were resuspended in growth medium including low-
glucose Dulbecco’s Modified Eagle’s Medium (Life Technolo-
gies, Grand Island, NY, http://www.thermofisher.com), 10%
fetal bovine serum (FBS; Life Technologies), and 1% penicillin/
streptomycin (Life Technologies). The ASCs at passage 3were used
for further studies.
Gene Transduction
Lentiviral particles (Santa Cruz Biotechnology, Dallas, TX, http://
www.scbt.com) containing short hairpin RNA (shRNA) targeting
noggin gene were used to transduce ASCs according to the man-
ufacturer’s instructions. Briefly, the cells were seeded onto six-
well plates and cultured until 50% confluence. The mixture
of shRNA lentiviral particles and polybrene (8 mg/ml; Sigma-
Aldrich) was then added to the culture medium and incubated
overnight. Stable clones expressing shRNAwere selectedwithpu-
romycin dihydrochloride (Sigma-Aldrich). Cells transduced with
lentiviral particles containing a scrambled shRNA sequence served
as negative controls.
Alkaline Phosphatase Activity and Alizarin Red Staining
Cells were cultured in 12-well plates with growth medium.
After 100% confluence, the medium was replaced with an
osteogenic medium containing 10 mM b-glycerophosphate
(Sigma-Aldrich), 50 mg/ml L-ascorbic acid (Sigma-Aldrich),
100 nM dexamethasone (Sigma-Aldrich), and phenamil (Sigma-
Aldrich) at various concentrations (0, 5, 10, or 20 mM). Af-
ter 3 days of culture, alkaline phosphatase (ALP) was stained
as previously described [22]. In brief, cells were fixed in 10%
formalin, rinsed with PBS, and incubated in a solution con-
taining Nitro Blue tetrazolium (Sigma-Aldrich) and 5-bromo-
4-chloro-3-indoxylphosphate (Sigma-Aldrich) stock solutions
in AP buffer (100mM Tris, pH 8.5, 50 mMMgCl2, 100mMNaCl)
for 1 hour. The stained samples were visualized with the Olym-
pus BX 51 microscope (Olympus, Center Valley, PA, http://
www.olympusamerica.com). ALP staining was further quanti-
fied by ImageJ software (NIH, Bethesda, MD). For the colori-
metric measurement of ALP activity, cells were lysed in 0.2%
NP-40 lysis buffer (Life Technologies) and measured at the ab-
sorbance of 405 nm by using p-nitrophenol phosphate sub-
strate (Sigma-Aldrich). Measurements were normalized to
total DNA content evaluated by the PicoGreen dsDNA Assay
(Life Technologies).
Calcium deposition was evaluated by using alizarin red stain-
ing as previously described [22]. After 14days, the fixed cellswere
incubated in 2% alizarin red staining solution (Sigma-Aldrich) for
5 minutes. The stained samples were observed with an Olympus
BX 51 microscope. To quantify mineralization, the stained cells
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were dissolved in 10% (vol/vol) acetic acid and measured at
the absorbance of 405 nm.
RNA Extraction andQuantitative Real-Time Polymerase
Chain Reaction
Cellular RNA extractionwas performedwith TRIzol reagent (Life
Technologies) and RNeasy Mini Plant kit (Qiagen, Valencia, CA,
https://www.qiagen.com) as previously described [22]. Briefly,
0.5 mg of total RNA was reverse-transcribed to cDNA by using a
cDNA transcription kit (Life Technologies). Quantitative real-
time polymerase chain reaction (qRT-PCR) was analyzed by us-
ing LightCycler 480 PCR (Roche, Indianapolis, IN, http://www.
roche.com) with 20 ml of SYBR Green reaction system. PCR am-
plification was run for 45 cycles. GAPDH expression level was
used to normalize other gene expression levels. The following
primers were used in this experiment: Runx2: CGGTCTCCTTCAG-
GATGGT (forward), GCTTCCGTCAGCGTCAACA (reverse); Osterix:
GCTAGAGATCTGAGCCGGGTA (forward), AAGAGAGCCTGGCAA-
GAGG (reverse); ALP: GTTGCCAAGCTGGGAAGAACAC (forward),
CCCACCCCGCTATTCCAAAC (reverse); Osteopontin (OPN): CTCCTGG
CTGAATTCTGAGG(forward), TGCCAGAATCAGTCACTTTCA (reverse);
Collagen1a1 (Col1a): AACCCGAGGTATGCTTGATCT (forward), CC
AGTTCTTCATTGCATTGC (reverse);Osteocalcin (OCN): GGGAGA-
CAACAGGGAGGAAAC (forward), CAGGCTTCCTGCCAGTACCT
(reverse); Noggin: CCGGGCTTTATGGCTACTTC (forward), TCCA-
GCCCTTTGATCTCG (reverse); Trb3: CTGAGGCTCCAGGACAAGA
(forward), CCTGCAGGAAACATCAGCA (reverse); GAPDH: AGGT-
CGGTGTGAACGGATTTG (forward), TGTAGACCATGTAGTTGAGGTCA
(reverse).
Western Blot Analysis
The Western blot assay was performed as previously described
[28]. In brief, after cellswere lysed in 0.2%NP-40 lysis buffer, total
cellular protein concentration was measured by using bicincho-
ninic acid protein assay (Thermo Scientific, Rockford, IL, http://
www.thermoscientific.com). The proteins were separated with
SDS-polyacrylamide gel electrophoresis, blotted onto Immobilon
polyvinyl difluoride membrane (Millipore, Billerica, MA, http://
www.emdmillipore.com), and detected with polyclonal anti-
bodies (Santa Cruz Biotechnology) for Noggin, Trb3, Smurf1,
Smad5, pSmad1/5/8, and GAPDH. The membranes were then in-
cubated with horseradish peroxidase (HRP)-conjugated second-
ary antibody (Millipore). The immunoreactive proteins were
subsequently visualized with chemiluminescent HRP (Denville
Scientific, South Plainfield, NJ, http://www.denvillescientific.
com).
Luciferase Assay
Id1 luciferase reporter assay was performed as previously de-
scribed [30]. Briefly, cells at 70%–80% confluence were cotrans-
fectedwithpGL4[luc2P/hID1/Hygro] Vector (Promega, Fitchburg,
WI, http://www.promega.com) and Renilla control vector (Prom-
ega) by using Lipofectamine 2000 (Life Technologies). After trans-
fection for 6 hours, cellswere treatedwith 20mMphenamil. After
48 hours of treatment, luciferase activities were measured by us-
ing a dual luciferase reporter system (Promega) and normalized
with Renilla internal control values.
Preparation of Scaffolds
PLGA scaffolds were fabricated by the solvent casting and partic-
ulate leaching technique as previously described [31, 32]. Sucrose
of 200- to 300-mm diameter was mixed with PLGA/chloroform
solution to reach 92%porosity (volume fraction) and compressed
into thin sheets with Teflon plates. Scaffolds were freeze-dried
to eliminate the residual solvents at 100 mTorr and 2110°C
(SP Industries, Warminster, PA, http://www.spindustries.com)
overnight. Sucrose was subsequently leached by immersing
scaffolds in double-distilled (dd) H2O. Then scaffolds were steril-
ized by immersion in 70% ethanol for 30 minutes, followed by
three rinses of sterile ddH2O. Finally, the scaffold sheets were
punched into 3-mm-diameter discs for further applications.
Biomimetic Apatite Coating Process
Apatite coating solution was prepared as described in previous
studies [31, 32]. Briefly, simulated body fluids (SBF) were formu-
lated by sequentially dissolving CaCl2, MgCl2·6H2O, NaHCO3, and
K2HPO4·3H2O into ddH2O. Adjustment of pH was made to 6.0,
and then Na2SO4, KCl, and NaCl were dissolved. The final solu-
tion was brought to a pH of 6.5 (SBF1). Mg2+ and HCO3
2 free
SBF (SBF2) was prepared by similarly dissolving CaCl2 and
K2HPO4·3H2O into ddH2O and pH was adjusted to 6.0. KCl and
NaCl were added, and the solution was adjusted to pH 6.8. All so-
lutions were sterile filtered by using a 0.22-mm polyethersulfone
membrane (Nalgene, Rochester, NY, http://nalgene.com). The
scaffold discs were subjected to glow discharge argon plasma
etching (Harrick Scientific, Pleasantville, NY, http://www.harricksci.
com). The etched scaffolds were immersed and incubated in
SBF1 for 24 hours and then further incubated in SBF2 for another
24 hours at 37°C. The apatite-coated scaffolds were washed with
sterile ddH2O to remove excess ions and lyophilized before
further studies.
Scanning Electron Microscopy
The internal morphology of Ap-PLGA scaffold was investigated
by scanning electron microscopy (Nova NanoSEM 230; FEI,
Hillsboro, OR, http://www.fei.com). The cross-sectioned samples
were mounted on aluminum stubs and sputter-coated with gold
at 20 mA under 70 mTorr for 50 seconds.
Release of Phenamil From Scaffolds
The release profile of Phenamil was analyzed as described previ-
ously [28]. Briefly, phenamilwas adsorbedonto scaffolds at a final
concentration of 300 mM and lyophilized in a freeze dryer for 3
hours. The phenamil-loaded scaffolds were incubated in 1 ml of
PBS (pH 7.4) supplemented with 10% FBS at 37°C. The whole in-
cubating solutionwas removedand replenishedwith 1ml of fresh
solution at predetermined timepoints over a span of 21 days. The
amount of released phenamil was evaluated by UV spectrometry
at an absorbance of 366 nm.
The bioactivity of phenamil released from the scaffolds was
assessed by measuring its ability to increase ALP activity in ASCs.
Phenamil-loaded scaffolds were incubated in the osteogenic me-
dium for 3 days, and the supernatant was collected for the assay.
Freshly reconstituted phenamil was used as a control. ASCs
were seeded onto 96-well plates at the final concentration of
1,000 cells per well and cultured in growthmedium. At the begin-
ning of the assay, the medium was replaced with osteogenic
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mediumsupplementedwith the scaffold supernatant at final phe-
namil concentration of 20 mM. After incubation for 3 days, ALP
activity was determined colorimetrically according to the meth-
ods described above.
Cell Proliferation and Differentiation on Scaffolds
To visualize the cell proliferation on the scaffolds, cell were
seeded onto apatite-coated PLGA scaffolds at the final concentra-
tion of 23 106 cells per milliliter, stained with a Live/Dead stain-
ing kit (Life Technologies) at 37°C for 15 minutes, and observed
under a fluorescence microscope (Olympus) at days 1 and 14. To
quantify thecellproliferationonthescaffolds, thecell/scaffoldcon-
structs were analyzed with the AlamarBlue assay kit (Life Technol-
ogies) at days 1, 3, 7, and 14. Briefly, the cell/scaffold constructs
were rinsedwithPBSand incubatedwith sterilized10%AlamarBlue
solution for 3 hours at 37°C. AlamarBlue fluorescence was mea-
sured at 535 nm (excitation) and 600 nm (emission). To measure
the osteogenic differentiation, cells on the scaffolds were cultured
with the osteogenicmediumandmeasured colorimetrically by ALP
activity at day 3 according to the methods described above.
Calvarial Defect Model
The calvarial defect model was performed in 2-month-old male
CD-1 nude mice (Charles River) to minimize the host immune re-
sponses to implanted cells. Calvaria of mice were trephine drilled
with constant irrigation to create 3-mm full-thickness craniotomy
defects in each parietal bone without damaging the underlying
dura mater as previously described [28]. Ap-PLGA scaffolds
loaded with or without phenamil (300 mM) were seeded with ei-
ther control shRNA or noggin shRNA-transduced ASCs. After im-
plantation, all animals were placed on a warm sheet for recovery
and then transferred to the vivarium for postoperative care. For
postoperative treatment, all mice received subcutaneous injections
of buprenorphine at the concentration of 0.1 mg/kg for 3 days.
Three-Dimensional Microcomputed
Tomography Scanning
At 6 weeks after implantation, animals were sacrificed, and
calvarial tissues were harvested for further analysis. The extracted
calvarial tissues were fixed in 4% formaldehyde at room tem-
perature with gentle shaking. After 48 hours of fixation, the
samples were rinsed with PBS and stored in 70% ethanol at 4°C
before imaging using the high-resolution microcomputed
tomography (microCT) machine (microCT SkyScan 1172; Bruker
MicroCT, Kontich, Belgium, http://bruker-microct.com) using
57 kVp, 184 mA, 0.5-mm aluminum filtration, and 10-mm resolu-
tion. All data were visualized and reconstructed by using Dolphin
3D software (Dolphin Imaging & Management Solutions, Chats-
worth, CA, http://www.dolphinimaging.com). New bone volume
and area were analyzed by using CTAn (Bruker MicroCT) and
ImageJ software. Bone specific analysis included new bone
area/original defect size (percent area), new bone volume/
tissue volume (percent BV/TV), and trabecular number
(TN×mm21).
Histological and Immunohistochemical Analyses
The fixed calvarial bone tissues were decalcified in 10% EDTA so-
lution with gentle shaking for 1 week. Decalcified samples were
embedded in paraffin and cut into sections of 5-mm thickness.
The tissue sections were deparaffinized and stained with hema-
toxylin and eosin (H&E). The deparaffinized slides were further
stained with 0.1% PicroSirius red solution (Polysciences, Inc.,
Warrington, PA, http://www.polysciences.com) and observed
under polarizing light microscope. Masson’s trichrome staining
was also used to detect new bone formation stained with light
green color. Additional sections were analyzed by immunohisto-
chemistry. The deparaffinized sections were treated by using cit-
ric acid antigen retrieval, incubated with the primary antibodies
(Santa Cruz Biotechnology) including Noggin, Trb3, pSmad1/5/8,
Runx2, and OCN, and stained by HRP/3,39-diaminobenzidine de-
tection kit (Abcam, Cambridge, MA, http://www.abcam.com)
according to the manufacturer’s instructions. The sections were
further counterstained with Mayer’s hematoxylin (Abcam). The
three random areas in each image were further quantified by
ImageJ software.
Statistical Analysis
Statistical analysis was performed by using one-way analysis of
variance, with the Tukey’s post hoc test when more than two
groups were compared. Student’s t test was used to compare
two groups. The data were presented as means 6 SD. p , .05
was considered statistically significant.
RESULTS
Osteogenic Differentiation of ASCs by Noggin
Suppression and Phenamil
The effects of noggin suppression and phenamil on osteogenesis
was investigated in ASCs transduced with noggin shRNA or con-
trol shRNA at various concentrations of phenamil (0, 5, 10, or
20 mM) (Fig. 1). Early osteogenic differentiation was detected
by ALP staining and quantification after 3 days of ASC culture
(Fig. 1A, 1B). Phenamil treatment dose-dependently increased
the expression of ALP as the phenamil concentration increased
from 5 to 20 mM, and noggin suppression further increased the
ALP expression in ASCs. The ALP expression was significantly
higher in ASCs treated with noggin shRNA and 20 mM phenamil
compared with the one detected in ASCs with control shRNA
(Fig. 1B).
The expression of osteogenic differentiation markers includ-
ing Runx2,Osterix, Col1a, ALP,OPN, andOCNwas examined with
qRT-PCR (Fig. 1C). Noggin shRNA increased the expression of
Osterix and Runx2, major transcription genes to regulate osteo-
genic differentiation, 5.8- and 1.7- fold, respectively. When fur-
ther stimulated with 20 mM phenamil, the Osterix and Runx2
expression level increased 33.8- and 3.8-fold, respectively, com-
pared with ASCs without phenamil treatment. ASCs treated with
noggin shRNA and 20 mM phenamil showed significant increase
on the ALP expression, confirming the results of ALP staining.
The expression levels of Col1a, OPN, and OCN were significantly
increased by noggin suppression, with strong promotion of these
genes when supplemented with phenamil (Fig. 1C).
Finally, the end-stage osteogenesis was investigated by ob-
serving extracellular matrix mineralization through alizarin red
staining on day 14 (Fig. 1D). The noggin suppression increased
the extent of mineralization in ASCs by 1.4-fold in the absence
of phenamil (Fig. 1E). Phenamil treatment (from 5 to 20 mM)
dose-dependently increased mineralization of ASCs treated with
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control shRNA by 1.4- to 2.4-fold, which was further increased
with noggin suppression by 2.6- to 3.5-fold (Fig. 1E).
BMP Signaling in ASCs Enhanced by Noggin Suppression
and Phenamil
Tounderstand themolecularmechanisms involved inosteogenesis
induced by noggin suppression and phenamil, we investigated the
expressionof noggin in ASCswith orwithout phenamil stimulation.
qRT-PCR results showed thatASCswithnoggin shRNA transduction
decreased the transcriptional level of the noggin gene by threefold
in the presence and absence of phenamil, compared with ASCs
transduced with control shRNA (Fig. 2A). We then investigated
the expression level of Trb3 because phenamil has been demon-
strated to enhance BMP signaling through upregulation of Trb3
(Fig. 2B). Phenamil treatment increased the mRNA level of Trb3
Figure 1. Noggin suppression and phenamil enhance osteogenic differentiation of ASCs in monolayer culture. Osteogenic markers were
assessed in ASCs transducedwith noggin shRNA or control shRNA in the presence or absence of phenamil. (A, B):ALP expression wasmeasured
by ALP staining and quantification at day 3. Scale bar = 500mm. (C):Osteogenic gene expression including Runx2,Osterix, ALP, Col1a,OPN, and
OCN, as analyzed by quantitative real-time polymerase chain reaction at day 3. Upregulation of all genes was noted in noggin shRNA cells in the
presence of phenamil. (D, E): Extracellular matrix mineralization was increased in noggin shRNA cells in the presence or absence of phenamil as
measured by AR staining and quantification at day 14. Data are presented asmeans6 SD (n = 3 per group). p, p, .05, pp, p, .01 versus control
shRNA. Abbreviations: AR, alizarin red; ASCs, adipose-derived stem cells; ALP, alkaline phosphatase; Col1a, Collagen1a1; ctrShRNA, control
shRNA; nogShRNA, Noggin shRNA; OCN, osteocalcin; OPN, osteopontin; Phe, phenamil; shRNA, short hairpin RNA.
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by 3.9- to 4.9-fold with or without noggin suppression. There was
no significant effect of noggin suppression on Trb3 expression
(Fig. 2B). Next, the effects of noggin suppression and phenamil
on BMP-Smad signaling were evaluated by Western blot for
Noggin, Trb3, Smurf1, and phosphorylated Smads (pSmad1/5/
8) (Fig. 2C, 2D). The downregulation of noggin protein expression
was confirmed inASCs treatedwithnoggin shRNA in the presence
or absence of phenamil. Furthermore, Trb3 protein expression
was significantly increased with phenamil treatment, regardless
of the presence of noggin shRNA. The increased amount of Trb3
downregulated the expression of Smurf1, which in turn enhanced
the expression level of pSmad1/5/8, which are major signal trans-
ducers for BMP (Fig. 2C, 2D). Most importantly, ASCs treated with
noggin shRNA and phenamil led to promote strong expression in
pSmad1/5/8 (Fig. 2D).We further confirmed the combined effects
of noggin suppression and phenamil treatment on BMP–Smad sig-
naling by examining the promoter activity of BMP-target gene Id1
using luciferase reporter assay (Fig. 2E). Id1 is one of the major
downstream targets of BMP signaling, and the BMP-induced Id1
expression was shown to be mediated by binding Smad proteins
Figure 2. Noggin suppression and phenamil stimulates BMP–Smad signaling pathway. (A): Noggin expression was downregulated in noggin
shRNA-treatedASCsasmeasuredby real-timePCR. (B):Phenamil-inducedexpressionofTrb3 inASCsasmeasuredby real-timePCR. (C):Western
blot analysis of Noggin, Trb3, Smurf1 at 24 hours. (D):Western blot analysis of Smad5, pSmad1/5/8 at 24 hours. (E): Id1 promoter activity was
measured by luciferase assay. (F): Schematic diagram of themechanism for the enhanced BMP–Smad signaling pathway by noggin suppression
and phenamil. Noggin suppression enhanced BMP–Smad signaling by increasing the phosphorylation of Smad 1/5/8 that was subsequently
stimulated by phenamil-induced Trb3 to reduce Smurf1 expression. Data presented as means 6 SD (n = 3 per group). p, p , .05, pp, p ,
.01 versus control shRNA. Abbreviations: ASCs, adipose-derived stem cells; BMP, bone morphogenetic protein; ctrShRNA, control shRNA;
nogShRNA, Noggin shRNA; Nog, Noggin; OCN, osteocalcin; PCR, polymerase chain reaction; Phe, phenamil; shRNA, short hairpin RNA; Smurf1,
ubiquitin ligase Smad ubiquitination regulatory factor; Trb3, tribbles homolog 3.
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toBMP-responsiveelements inthe Id1promoter [33,34].Phenamil
treatment increased the Id1 luciferase activity by 1.7-fold in ASCs,
which was further increased by 5.1-fold with noggin suppression
comparedwith thecontrol shRNAgroup (Fig. 2E), indicating theen-
hanced BMP–Smad pathway in ASCs.
ASCs Cultured on Apatite-Coated PLGA Scaffolds
Releasing Phenamil
To evaluate the ability of Ap-PLGA scaffolds to support
growth of noggin knockdown ASCs and deliver phenamil,
three-dimensional (3D) porous PLGA scaffolds were fabri-
cated and coated with apatite as described in our previous
studies [31, 32]. A uniform layer of apatite coating with
plate-like morphology was observed on the surface (Fig.
3A). The created Ap-PLGA scaffolds were loaded with phena-
mil (300 mM), and the release kinetic was measured by incu-
bating the scaffolds in a PBS solution supplemented with
10% FBS. The Ap-PLGA scaffolds released phenamil in a sus-
tained manner up to day 21, with approximately 27% of initial
burst release (Fig. 3B).
Figure 3. ASCs cultured on the Ap-PLGA scaffolds. (A): Scanning electron microscopic images of Ap-PLGA scaffolds. Inset shows high magni-
fication of apatite coating. (B): In vitro release profile of phenamil fromAp-PLGA scaffolds. (C, D):Bioactivity of phenamil released fromAp-PLGA
scaffolds. Scale bar = 200 mm. (E): Proliferation of ASCs in the Ap-PLGA scaffolds loaded with phenamil as assessed by Live-Dead fluorescent
staining at days 1 and 14. Scale bar = 500mm. (F):Quantification of the ASC proliferation with AlamarBlue Assay at days 1, 3, 7, and 14. (G): ALP
activity ofASCs inAp-PLGAscaffolds increasedwithnoggin suppressionandphenamil. Datapresentedasmeans6SD (n=3per group).p,p, .05
versus control shRNA. Abbreviations: ALP, alkaline phosphatase; Ap-PLGA, apatite-coated poly(lactic-coglycolic acid); ASCs, adipose-derived
stem cells; ALP, alkaline phosphatase; ctrShRNA, control shRNA; nogShRNA, Noggin shRNA; Phe, phenamil; shRNA, short hairpin RNA.
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The bioactivity of phenamil released from Ap-PLGA scaffolds
was determined by examining ALP expression in ASCs. The super-
natant collected from phenamil-loaded scaffolds increased the
ALP stain and activity of ASCs to a similar extent to that of freshly
reconstituted phenamil (Fig. 3C, 3D).
Tomeasure cell proliferation in 3D scaffold, ASCs treatedwith
control shRNA and noggin shRNA were seeded on the scaffolds
with or without phenamil and observed with Live/Dead staining
(Fig. 3E). All experimental groups showed a high level of cell via-
bility (. 95%) over the 14-day culture period. Significantly higher
cell proliferation was observed in the ASCs treated with both
noggin shRNA and phenamil than other groups, as indicated by
AlamarBlue assay (Fig. 3F). The feasibility of Ap-PLGA scaffolds
to support osteogenic differentiation was further assessed by
monitoring ALP activity of ASCs seeded on the scaffolds at day
3. Noggin knockdown ASCs increased the ALP activity by 3.5-fold
on the scaffolds without phenamil compared with that detected
in control ASCs,whichwas further increased by4.5-foldwhen cul-
tured on the scaffolds loaded with phenamil (Fig. 3G).
BMP Signaling and Osteogenesis Enhanced by Noggin
Suppression and Phenamil In Vivo
To examine the combined effect of the noggin suppression and
phenamil on BMP signaling and subsequent osteogenesis in vivo,
ASCs treated with noggin shRNA were seeded on phenamil-
loaded scaffolds and implanted into critical-sized calvarial de-
fects. There was no significant difference in bone healing among
the experimental groups at 2weeks postoperatively, although lit-
tle healing was observed at the edge of the defects treated with
noggin-suppressed ASCs as demonstrated by H&E and Masson’s
Trichrome staining (Fig. 4A; supplemental online Fig. 1).
Noggin shRNA transduction led to significant reduction in the
expression level of noggin within the defects compared with the
defects treated with control shRNA in the presence and absence
of phenamil, as demonstrated by immunohistochemical staining
for noggin (Fig. 4B, 4E). Furthermore, defects treatedwith phena-
mil significantly increased the expression of Trb3 compared with
defects implanted with phenamil-free scaffolds (Fig. 4C, 4F).
Lastly, noggin shRNA transduction or phenamil treatment increased
Figure 4. Noggin suppression and Phenamil accelerated BMP–Smad signaling pathway in vivo. (A): Histological staining of calvarial defects
treated with phenamil-loaded Ap-PLGA scaffolds seeded with Noggin shRNA-transduced ASCs at 14 days postoperatively. Images were taken
at34 magnification. Scale bar = 500 mm. (B–D): Immunohistochemistry staining for Noggin, Trb3, and pSmad 1/5/8 expression. Images were
taken at340magnification. Scale bar = 50mm. (E–G): Semiquantification of immunohistochemical staining for Noggin, Trb3, and pSmad 1/5/8.
Data are presented as means6 SD (n = 9 per group). p, p, .05, pp, p, .01 versus blank scaffold. Abbreviations: Ap-PLGA, apatite-coated poly
(lactic-coglycolic acid); ASCs, adipose-derived stem cells; BMP, bone morphogenetic protein; ctrShRNA, control shRNA; nogShRNA, Noggin
shRNA; Nog, Noggin; OCN, osteocalcin; Phe, phenamil; shRNA, shRNA, short hairpin RNA; Trb3, tribbles homolog 3.
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BMP signaling activity as indicated by increased pSmad1/5/8 in the
defects (Fig. 4D, 4G). TheexpressionofpSmad1/5/8was significantly
higher in defects treated with both noggin shRNA transduction and
phenamil comparedwith groups implantedwith noggin knockdown
ASCs or phenamil alone (Fig. 4D, 4G). In addition, the enhancedBMP
activity ledto increasedosteogenicdifferentiation indefects,asdem-
onstrated by immunohistochemical staining for osteogenic markers
including Runx2 andOCN (Fig. 5A, 5B). Semiquantification of the im-
munohistochemical staining revealed that phenamil-releasing scaf-
folds seeded with noggin shRNA-transduced ASCs displayed the
most intenseRunx2andOCNstaining thanothergroups (Fig.5C,5D).
ASCs Enhanced Calvarial Bone Formation by Noggin
Suppression and Phenamil
Lastly, we evaluated the combined effect of noggin suppression
and phenamil on ASCs for bone repair in a calvarial defect model.
At 6 weeks after operation, microCT images demonstrated that
scaffolds seeded with noggin shRNA-transduced ASCs significantly
increased calvarial healing compared with control shRNA groups
(Fig. 6A). Minimal bone healing was observed in calvarial defects
treated with blank scaffolds. In contrast, calvarial defects treated
with phenamil-releasing scaffolds displayed enhancedbone regen-
eration in the presence and absence of ASCs, and almost complete
bone healing was obtained after 6 weeks through combination
treatmentof noggin knockdownandphenamil stimulations.More-
over, only the defects in the combinatorial treatment developed a
complete bone bridge crossing the defect area (Fig. 6B).
Quantification of microCT images evaluated new bone area,
bone volume fraction, and trabecular number within the defects
(Fig. 6C26E). Results showed that defects treated with noggin
shRNA-transduced ASCs and phenamil increased the bone heal-
ingextent to97.5%and65% inboneareaandBV/TVafter6weeks,
whereas the calvarial defects treatedwithblank scaffolds showed
bone healing less than 3% (Fig. 6C, 6D). Likewise, there was a sig-
nificant increase in the trabecular number within the defects
treated with both noggin shRNA-transduced ASCs and phenamil
compared with that detected in the other experimental groups
(Fig. 6E).
MicroCT findings were further confirmed by histological anal-
ysis with H&E staining (Fig. 7A) and Masson’s trichrome staining
(Fig. 7B). Results showed that noggin suppression + phenamil
groups resulted in mature bone and thick osteoid matrix forma-
tion completely bridging and spanning the defect area after
6weeks. Complete ossificationwas not apparent in defects treat-
edwithnoggin shRNA-transducedASCsorphenamil alone. In con-
trast to the other groups, a large amount of trabecular bone
formation was observed throughout the defects treated with
both noggin suppression and phenamil, as detected by Masson’s
trichrome staining (Fig. 7B). Collagen organization in the defect
area was evaluated by PicroSirius red staining with polarized mi-
croscopy (Fig. 7C). Higher collagendepositionwasobserved inde-
fects treated with noggin suppression and phenamil compared
with the other groups. Birefringence of these collagen fibers re-
sembled that of collagen fibers that are found in native calvarial
bones (Fig. 7C). In addition, immunohistochemical staining for
OCN, a protein associated with bone matrix mineralization,
revealed that the production of OCN was increased in defects
treatedwith noggin suppression and phenamil (Fig. 7D). In partic-
ular, the defects treated with phenamil in presence or absence
Figure 5. Noggin suppression and phenamil increased expression of osteogenicmarkers within calvarial defects. (A, B): Immunohistochemical
staining for Runx2 and OCN expression in calvarial defects treated with phenamil-loaded Ap-PLGA scaffolds seeded with noggin shRNA-trans-
duced ASCs at 14 days postoperatively. Scale bar = 50mm. (C, D): Semiquantification of immunohistochemical staining for Runx2 andOCN. Data
are presented asmeans6 SD (n = 9 per group). p, p, .05, pp, p, .01 versus blank scaffold. Abbreviations: Ap-PLGA, apatite-coated poly(lactic-
coglycolic acid); ASCs, adipose-derived stem cells; ctrShRNA, control shRNA; nogShRNA, Noggin shRNA; OCN, osteocalcin; phe, phenamil;
shRNA, short hairpin RNA; w/, with; w/o, without.
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Figure 6. Noggin suppression and phenamil enhanced calvarial bone repair. (A):microCT images of calvarial defects treated with phenamil-
loaded Ap-PLGA scaffolds seeded with noggin shRNA-transduced ASCs at 6 weeks postoperatively. (B): Sagittal microCT images. Arrowhead
indicates approximate margins of bone defects. (C): Quantification of percent bone area. (D): Quantification of percent BV/TV. (E): Quantifi-
cation of Tb.N (mm21). Data are presented as means6 SD (n = 10 per group). p, p, .05, pp, p, .01 versus blank scaffold. Abbreviations:
Ap-PLGA, apatite-coated poly(lactic-coglycolic acid); ASCs, adipose-derived stem cells; BV/TV, bone volume/tissue volume; microCT,
microcomputed tomography; ctrShRNA, control shRNA; nogShRNA, Noggin shRNA; Phe, phenamil; shRNA, short hairpin RNA; Tb.N, tra-
becular number; w/, with; w/o, without.
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of ASCs showed strong OCN production in nonbone healing area
compared with blank scaffold controls (Fig. 7D).
DISCUSSION
Current studies postulate that manipulating levels of BMP-
signaling antagonists and agonists is critical to osteogenesis of
ASCs. BMPs bind to and activate the receptors to phosphorylate
SMAD1/5/8, which in turn are translocated into the nucleus in
complex with SMAD4, ultimately regulating the transcription of
the BMP target genes [6, 35]. The BMP–Smad signaling regulates
stem cell self-renewal and differentiation, embryonic develop-
ment, and postnatal tissue homeostasis, including bone homeo-
stasis [6, 35]. From genetic studies in vitro and in vivo, the
disruption of BMP–Smad signaling is associated with various
bone-related diseases, such as osteoporosis, heterotopic ossifi-
cation, and bone fracture mass [36, 37]. Thus, the BMP–Smad
signaling pathway is an effective therapeutic target in the treat-
ment of bone disorders. Our approach here is to enhance
endogenous BMP–Smad activities by knocking down noggin
expression in ASCs while simultaneously delivering phenamil
to maximize osteoinduction and minimize potential adverse ef-
fects of current BMP-based therapeutics. Endogenous BMPs are
likely to exist as heterodimericmolecules that are reported tobe
more potent in inducing bone formation compared with their
respective homodimeric molecules [35, 36]. Given the rela-
tively low bioactivity of recombinant BMPs and their high dose
requirement in clinical applications, enhancing endogenous
BMP activity through the suppression of noggin will lead to
much safer and more efficient bone regeneration and is dis-
tinctly advantageous to the application of exogenous BMPs.
In the present study, we demonstrated enhanced endogenous
BMP signaling by downregulating noggin to promote osteogenic
differentiation of ASCs and bone healing.
We further used the smallmolecule phenamil to complement
the endogenous BMP activity mediated by noggin suppression.
The small molecule phenamil was documented as a strong
BMP signaling stimulator [25]. Our previous study demon-
strated that phenamil additively increased osteogenic differen-
tiation and bone repair with BMP-2 [28]. Furthermore, the
Figure 7. Histological and immunohistochemical analysis of bone regeneration in calvarial defects treated with noggin suppression and phe-
namil. (A):Histological stainingof calvarial defects treatedwithphenamil-loadedAp-PLGAscaffolds seededwithnoggin shRNA-transducedASCs
at 6 weeks postoperatively. Dashed lines indicate relative nonhealing area. Arrowhead indicates new bone tissues. Area within the black box
indicates the high magnification of image below. Images were taken at34 (top image) and340 (bottom image) magnification. Scale bars =
500 mm (top) and 50 mm (bottom). (B):Masson’s trichrome staining. Area within the red box indicates the high magnification of the image below.
Imageswere taken at34magnification for top image and320magnification for bottom image. Scale bars =500mm(top) and100mm(bottom).
(C):Sirius red stainingatpolarized light.Arrowhead indicates theexpressionof collagen thatnormally exists innative calvarial bone. Imageswere
takenat340magnification. Scalebar =50mm. (D): Immunohistochemical staining forOCN. Imageswere takenat340magnification. Scale bar =
50 mm. Abbreviations: Ap-PLGA, apatite-coated poly(lactic-coglycolic acid); ASCs, adipose-derived stem cells; ctrShRNA, control shRNA;
nogShRNA, Noggin shRNA; OCN, osteocalcin; Phe, phenamil; shRNA, short hairpin RNA; w/, with; w/o, without.
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combination treatment of phenamilwith BMP-2 significantly re-
duced the exogenous BMP-2 doses required for effective osteo-
genesis and bone healing. The osteogenic activity of phenamil is
believed to be mediated by activation of Trb3 that stabilizes
SMADs, major signal transducers for BMPs, by inhibiting the ex-
pression of BMP antagonist Smurf1 [25]. In this study, we demon-
strated that the phenamil treatment can promote Trb3 expression
in ASCs and calvarial defects to enhance BMP signaling and osteo-
genesis. The present studies also showed that phenamil treatment
with noggin suppression highly enhanced BMP signaling activity in
vitro and within calvarial defects compared with control shRNA or
phenamil-alone groups, as demonstrated by Western blot or im-
munohistochemical staining for Smads. The observed bone forma-
tionwas comparable to bone healing found in defects treatedwith
BMP-2 [28], suggestingthat thecombinedtreatmentofnoggin sup-
pression and phenamil may provide an efficient potential cell-
based bone regeneration strategywithout the need for exogenous
application of supraphysiological BMP doses.
In this study, Ap-PLGA scaffolds were used to deliver noggin-
suppressed ASCs and small-molecule phenamil. We have exten-
sively studied biomimetic processing approaches to create apatite
layers on the various surfaces of complex 3D scaffolds or particles
including PLGA, chitosan, and tricalcium phosphate [31, 32, 38]. The
apatite microenvironment created on biomaterial surfaces stimu-
lated adipose-derived or bone marrow-derived progenitor cells to
differentiate into osteoblastic cells and repaired bone defects [39,
40]. Besidespromotingosteogenic activities of progenitor cells, the
biomimetic apatite coating also served a favorable substrate to de-
liver bioactive molecules [31, 32, 38]. Our study showed that a
high amount of phenamil was successfully loaded on the Ap-PLGA
scaffolds, and loaded phenamil was slowly released in serum-
containingmediumup to 21 days. This may be because of the high
surface area from the plate-likemorphology of the created apatite
coating, resulting in high drug retention capacity. Controlled deliv-
ery of bisphosphonateor simvastatinmolecules has been reported
using calcium phosphate substrates [41–43]. Furthermore, phena-
mil released from the Ap-PLGA scaffolds exhibited ALP activity
comparable to freshly reconstituted phenamil, indicating that
the bioactivity of phenamil was preserved during the loading pro-
cess onto apatite layers. However, phenamil was nonspecifically
adsorbed on a scaffold surface, and such physical adsorption-
based delivery is often easily affected by scaffold degradation
and tissue ingrowth. Given the narrow therapeuticwindowof phe-
namil, due to its hydrophobicity and dose-dependent toxicity [28],
further studywillbeneededtobettercontrol thedeliveryof thismol-
ecule by developing a stand-alone nanoparticle carrier that can be
integrated with the scaffolds. Moreover, the phenamil-loaded scaf-
fold significantly enhanced proliferation and osteogenic differentia-
tion of ASCs treated with noggin shRNA. The observed higher cell
proliferationaswell as osteogenic differentiationmay facilitatebone
healing by increasing the number of progenitor cells and the depo-
sition of bone matrix. These results indicate that the combination
treatment may be efficient for bone formation strategies in situa-
tions where maximal bone regeneration is required. However, we
recognize that prolonged phenamil treatment and lack of noggin
may induce undesirable tissue overgrowth or bone lesions. Addi-
tional studies on controlled deliverymodalitieswill beneeded for ef-
fective and safer deliver of phenamil and siRNA molecules.
In addition, the high BMP2 doses required for human osteo-
genesis are associated with life-threatening inflammatory cervi-
cal swelling and adipogenic cyst-like bone formation [44, 45].
Interestingly, Trb3 was revealed to inhibit expression of peroxi-
some proliferator-activated receptorg, amaster regulator of adi-
pogenesis, and serves as a negative regulator of proinflammatory
cytokines [46–48]. The additional knowledge gained from this
studymay suggest a newcomplementary osteoinductive strategy
using phenamil with noggin suppression to maximize osteogenic
differentiation of ASC for bone regeneration andminimize poten-
tial adverse effects of current osteoinductive therapeutics.
CONCLUSION
We demonstrated a strategy to enhance the BMP-signaling path-
way in osteogenesis of ASCs without exogenous application of
BMPs by regulating levels of antagonists and agonists to BMP sig-
naling. The treatment of phenamil combined with the employ-
ment of noggin suppression significantly enhanced osteogenic
differentiation of ASCs in vitro and calvarial bone formation in
vivo through increased BMP–Smad signaling. The results indicate
that the complementary approach may present novel stem cell-
based therapeutic strategies in bone repair in a safe and cost-
effective way.
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